Pogue geile



Keywords: antibodies, monoclonal, humanized;antineoplastic agents;breast neoplasms;chemotherapy, adjuvant;cohort studies;estrogen receptor alpha;female;gene expression profiling;humans;odds ratio;predictive value of tests;principal component analysis;proportional hazards models;rna, messenger;receptor, erbb-2;trastuzumab;treatment outcome
Description: J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21. Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

BACKGROUND: National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31.

METHODS: Case subjects with tumor blocks were randomly divided into discovery (n = 588) and confirmation cohorts (n = 991). A predictive model was built from the discovery cohort through gene expression profiling of 462 genes with nCounter assay. A predefined cut point for the predictive model was tested in the confirmation cohort. Gene-by-treatment interaction was tested with Cox models, and correlations between variables were assessed with Spearman correlation. Principal component analysis was performed on the final set of selected genes. All statistical tests were two-sided.

RESULTS: Eight predictive genes associated with HER2 (ERBB2, c17orf37, GRB7) or ER (ESR1, NAT1, GATA3, CA12, IGF1R) were selected for model building. Three-dimensional subset treatment effect pattern plot using two principal components of these genes was used to identify a subset with no benefit from trastuzumab, characterized by intermediate-level ERBB2 and high-level ESR1 mRNA expression. In the confirmation set, the predefined cut points for this model classified patients into three subsets with differential benefit from trastuzumab with hazard ratios of 1.58 (95% confidence interval [CI] = 0.67 to 3.69; P = .29; n = 100), 0.60 (95% CI = 0.41 to 0.89; P = .01; n = 449), and 0.28 (95% CI = 0.20 to 0.41; P < .001; n = 442; P(interaction) between the model and trastuzumab < .001).

CONCLUSIONS: We developed a gene expression-based predictive model for degree of benefit from trastuzumab and demonstrated that HER2-negative tumors belong to the moderate benefit group, thus providing justification for testing trastuzumab in HER2-negative patients (NSABP B-47).






Photogallery Pogue geile:


R. Sean Gallagher


Accommodations | jenn and ethan get married


Accommodations | jenn and ethan get married


Accommodations | jenn and ethan get married


Accommodations | jenn and ethan get married


Accommodations | jenn and ethan get married


Accommodations | jenn and ethan get married


A rapid, sensitive, reproducible and cost-effective method for ...


Social and Cognitive Abilities in Late Childhood - Springer


Psychological Medicine - <em>Behavior Genetic Principles ...


Genetics in Medicine - Table 1 for article: Hereditary, familial ...


Apport de l'oncogntique en cancrologie digestive - Springer


Nucleotide sequence analysis of in vivo recombinants between ...


Genetics in Medicine - Table 3 for article: Hereditary, familial ...


Gene Structure and Expression in Colorectal Cancer - Springer


macdonaldvita05.doc


macdonaldvita05.doc


macdonaldvita05.doc